Evidence of Klebsiella Pneumoniae and SARS-CoV-2 Infections among Patients Pesenting with Cough and Fever Attending Chest Clinic, Aminu Kano Teaching Hospital, Kano
Keywords:
Bacteria, Klebsiella pneumoniae, antibiotics, COVID-19, RT-PCR, co-infections, SARS-CoV-2Abstract
Extensive antibiotic use during early COVID-19 management may reduce bacterial co-infection but contributes to increasing antibiotic resistance, particularly in Klebsiella pneumoniae. Accurate detection of K. pneumoniae is therefore important to support diagnosis and treatment of COVID-19 patients. This study aimed to identify and detect K. pneumoniae and SARS-CoV-2, and to assess associated demographic characteristics and comorbidities among patients attending the chest clinic at Aminu Kano Teaching Hospital (AKTH), Kano. Demographic data and risk factors were collected using questionnaires. A total of 300 sputum samples were cultured on MacConkey agar and incubated aerobically at 37°C, followed by phenotypic identification using standard biochemical tests. SARS-CoV-2 was detected using real-time PCR. The prevalence of K. pneumoniae and SARS-CoV-2 infections was 17.0% and 3.3%, respectively, with a co-infection rate of 1.3%. Males showed a higher prevalence of K. pneumoniae infection (64.7%) than females (35.3%). Common symptoms included cough and fever. The findings highlight the association of respiratory tract infections with K. pneumoniae and emphasize the need for routine diagnostic testing to detect and manage co-occurring respiratory infections in COVID-19 patients.
References
Blasco, M.L., Buesa, J., Colomina, J., Forner, M.J., Galindo, M.J., Navarro, J., Noceda, J., Redón, J., Signes-Costa, J. and Navarro, D. (2020), Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia. Journal of Medical Virology. 92, 1799-1801.
Budiarti, C. A., Ghisetti, V., Burdino, E., Trunfio, M., Allice, T., Boglione, L., (2022). Co-infection with other respiratory pathogens in COVID-19 patients. Clinical Microbiology and Infection. 27(2), 297-298.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research. 178, 104787.
Center for Disease Control (2020). Antibiotic Resistance Threats in the United States, 2020.
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 25(3), 2000045
Cornelius, C. J. and Nguyen M. H. (2020). COVID-19, superinfections and antimicrobial development: What can we expect. Clinical Infectious Diseases. 109-143.
Gomez, S., Obiamiwe, U., Henry, G. and Burke, A. C. (2015). Mortality and morbidity of Klebsiella pneumoniae infection. American Journal of Physicians. 25 (5), 52 – 100.
Guo, D., Dong, N., Zheng, Z., Lin, D., Huang, M. and Wang, L. (2019). A fatal outbreak of ST1carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. Lancet Infectious Diseases. 18, 37–46.
Hughes, B., Vallon, M., Zai, J. and Chaillon, A. (2020). Transmission dynamics and evolutionary history of 2019‐nCoV. Journal of Medical Virology. 92(5), 501-511
Huttner, B., Catho, G., Pano-Pardo, J. R., Pulcini, C. and Schouten, J. (2020). COVID-19 Antimicrobial stewardship principles. Clinical Microbiology Infection. 26, 808e10.
Lansbury, L., Lim, B., Baskaran, V. and Lim, W. S. (2020). Co-infections in people with COVID-19: a systematic review and meta-analysis. Journal of Infection. 81(2), 266-275.
Liu, C. C., Shih, T. P., Ko, W. C., Tang, H. J. and Hsueh, P. R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-cov-2) and coronavirus disease-2019 (COVID19): The epidemic and the challenges. International Journal of Antimicrobial Agents. 55(3), 105924.
Montero, M., D. W., Sun, K., J., Mirzaei, R., Goodarzi, P., Asadi, M. (2020). Bacterial co-infections with SARS-CoV-2. Immune dysfunction and bacterial coinfections following influenza. IUBMB Life. 72, 2097–2111.
Musaif, A., M., Alvi, I. and Rehman, S. (2021). Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infectious Drug Resistance. 21(11), 1249-1260.
Ochei, J. and Kolhatkar, A. (2008). Medical Laboratory Science, Theory and Practices. McGraw-Hill Education. 311-347.
Ogunsola, O., Öksüz, S., Acar, A., Ülkür, E., Turhan, V., Uygur, F. and Görenek, L. (2018). Nosocomial infection characteristics of klebsiella pneumoniae in a burn intensive care unit: analysis of an eleven-year active surveillance. Burns. 40 (5), 835-841.
Ravichitra, K. N., Prakash, H. P., Subbarayudu, S. and Rao, S. U. (2014). Isolation and antibiotic sensitivity of Klebsiella pneumoniae from pus, sputum and urine samples. International Journal of Current Microbiology and Applied Sciences. 3(3), 115-119.
Rosana, N., G., Khani M., Hodadadi J., Fotouhi-Ardakani R., Koohpaei A. (2020). Evaluation of bacterial co-infections of the respiratory tract in Covid-19 patients admitted to ICU. BMC Infectious Diseases. 20(1), 646.
Tan, A. N., Khan, M., Saleem, W., Karobari, M. I., Mohamed, R. N., Haboyan, A. and Alestad, J. H. (2022). Evaluation of bi-lateral coinfection and antibiotic resistance rates among COVID-19 patients. Journal of Antibiotics. 3(2), 5456.
World Health Organization (WHO), (2020). Laboratory testing for coronavirus disease COVID-19 in suspected human cases. Interim guidance, (No. 08 WHO/COVID-19/laboratory/2020.
Wu, Z., B., Liu, S. and Tan, T. (2020). Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest Medicine. 158(1),9–13.
Ye, C., Zhang, S., Zhang, X., Cai, H., Gu, J., Lian, J., ... & Yang, Y. (2020). Impact of comorbidities on patients with COVID‐19: A large retrospective study in Zhejiang, China. Journal of medical virology. 92(11), 2821-2829.
Downloads
Published
How to Cite
Issue
Section
Total Views: 18
| 
Total Downloads: 5
